EXPRESSION AND ACTIVITY OF CYP2C8 AND 2C9 IN DIABETES MELLITUS AND NONALCOHOLIC FATTY LIVER DISEASE

Ghadah Alghaith

University of Rhode Island, g.alghaith@hotmail.com

Follow this and additional works at: https://digitalcommons.uri.edu/theses

Recommended Citation
Alghaith, Ghadah, "EXPRESSION AND ACTIVITY OF CYP2C8 AND 2C9 IN DIABETES MELLITUS AND NONALCOHOLIC FATTY LIVER DISEASE" (2018). Open Access Master's Theses. Paper 1400.
https://digitalcommons.uri.edu/theses/1400

This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
EXPRESSION AND ACTIVITY OF CYP2C8 AND 2C9 IN DIABETES MELLITUS AND NONALCOHOLIC FATTY LIVER DISEASE

BY

GHADAH ALGHAITH

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN
PHARMACEUTICAL SCIENCES

UNIVERSITY OF RHODE ISLAND
2018
MASTER OF SCIENCE THESIS

OF

GHADAH ALGHAITH

APPROVED:

Thesis Committee:

Major Professor       Fatemeh Akhlaghi

Nisanne Ghonem

Sheron Wen

Nasser H. Zawia

DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2018
ABSTRACT

Background and Objectives:

Diabetes mellitus and Non-Alcoholic Fatty Liver Disease (NAFLD) are two highly prevalent and related diseases. Research have shown that they can affect the expression and activity of enzymes integral in the clearance of xenobiotics. Such enzymes include the Cytochrome P-450 isoforms 2C8 and 2C9. Our objective is to study the effect of these diseases on CYP2C8 and CYP2C9 using in vitro tools.

Methods:

A bank of donated livers was utilized for in vitro studies. Hepatic microsomal incubations of S-warfarin, a (CYP2C9) probe substrate, were performed to measure CYP2C9 activity by product formation and S-warfarin’s intrinsic clearance by in vitro half-life approach. Additionally, previously acquired data in our lab on mRNA and protein levels of CYP2C8 and CYP2C9 have been analyzed and compared among diabetic and NAFLD groups.

Results and Conclusions:

Analysis of CYP2C8 mRNA and protein expression in addition to CYP2C9 mRNA expression, activity, and warfarin’s intrinsic clearance showed no significant alteration by NAFLD nor diabetes. CYP2C9 protein expression significantly varied between different diabetic and NAFLD populations (p = 0.047).
ACKNOWLEDGEMENTS

I would first like to greatly thank my thesis advisor Dr. Fatemeh Akhlaghi of the College of Pharmacy at University of Rhode Island. She has been greatly supportive and encouraging to me both on the professional and personal levels. She consistently allowed this research to be my own work while pointing me in the right direction and providing recommendations whenever she thought I needed it.

Huge thanks to my committee members Dr. Nisanne Ghonem and Dr. Sheron Wen for their constructive feedback and suggestions to improve my work.

I would also like to thank all my lab mates in Akhlaghi’s group. Special thanks to my former lab mates Dr. Sravani Adusumalli and Dr. Enoch Cobbina for their mentorship. Also, my current lab mates Dr. Armin Sadighi, Dr. Rohitash Jamwal, Ben Barlock, and Anitha Sravankumar for being helpful and collaborative.

Finally, my sincere gratitude to my mother Jawaher Aljalajel and my husband Khalid Alluhaybi for being my light and hope in the darkest days.
# TABLE OF CONTENTS

ABSTRACT .......................................................................................................................... ii

ACKNOWLEDGMENTS ...................................................................................................... iii

TABLE OF CONTENTS ....................................................................................................... iv

LIST OF TABLES ................................................................................................................ v

LIST OF FIGURES ............................................................................................................. vi

LIST OF ABBREVIATIONS .................................................................................................. vii

CHAPTER 1 INTRODUCTION AND REVIEW OF LITERATURE ........................................... 1

CHAPTER 2 METHODOLOGY .............................................................................................. 26

CHAPTER 3 RESULTS ......................................................................................................... 36

CHAPTER 4 DISCUSSION AND CONCLUSIONS ................................................................ 46

BIBLIOGRAPHY .................................................................................................................. 48
# LIST OF TABLES

| TABLE | PAGE |
|-------|------|
| Table 1. Influence of Diabetes Mellitus on Pharmacokinetics (Studies reported between 1/1/2012 – 9/4/2018). | 6 |
| Table 2. Donors’ demographics and detected CYP2C8/2C9 inducers and inhibitors in all livers (n=106) | 28 |
| Table 3. Donor’s demographics and detected CYP2C9 inducers/inhibitors in livers included in CYP2C9 activity measurements (n=76) | 30 |
| Table 4. Intrinsic clearance (mL/min/kg) values for individual liver samples | 39 |
| Table 5. Effect of diabetes and NAFLD on S-warfarin’s intrinsic clearance | 40 |
| Table 6. Effect of diabetes and NAFLD on CYP2C9 activity | 41 |
| Table 7. Effect of diabetes and NAFLD on CYP2C8 and CYP2C9 mRNA expression | 42 |
| Table 8. Effect of diabetes and NAFLD on CYP2C8 and CYP2C9 protein expression | 43 |
| Table 9. Pairwise comparisons of CYP2C9 protein levels distribution between disease groups | 44 |
| FIGURE  | PAGE |
|---------|------|
| Figure 1. LC-MS/MS system linearity for injected analyte concentration versus detected response. | 36 |
| Figure 2. Range of linearity of S-7OH-warfarin formation with respect to incubation time and microsomal concentration. | 37 |
| Figure 3. Michaelis-Menten Plots at 45 and 60 minutes incubation times. | 37 |
| Figure 4. Boxplots representing the distribution of CYP2C9 protein levels across NAFLD subgroups within the diabetic group. | 38 |
LIST OF ABBREVIATIONS

AUC: Area Under the Concentration-Time Curve Until the Last Quantifiable Value

CAR: Constitutive Androstane Receptor

CL: Clearance

Cmax: Maximum Observed Plasma Concentration

CYP: Cytochrome P450 Enzyme System

DMEs: Drug Metabolizing Enzymes

EETs: Epoxyeicosatrienoic Acids

g: grams

HLM: Human Liver Microsomes

IS: Internal Standard

Ke: Elimination Rate Constant

kg: kilograms

LC-MS/MS: Liquid Chromatography-Tandem Mass Spectrometry

min: minutes

mRNA: Messenger Ribonucleic Acid

n: number of samples
NADPH: Nicotinamide Adenine Dinucleotide Phosphate

NAFL: Non-Alcoholic Fatty Liver

NAFLD: Non-Alcoholic Fatty Liver Disease

NASH: Non-Alcoholic Steatohepatitis

NSAID: Non-Steroidal Anti-Inflammatory Drug

PBPK: Physiologically-Based Pharmacokinetics

PK: Pharmacokinetics

PXR: Pregnan X Receptor

SD: Standard Deviation

T ½: Elimination Half-Life

T2DM: Type 2 Diabetes Mellitus

Tb: Tuberculosis

Tmax: Time to Reach Maximum Concentration (Cmax)

UGT: Uridine 5'-diphospho-glucuronosyltransferase enzyme system

Vd: Volume of Distribution

v: volume
Chapter 1

Literature Review

Pathological conditions can produce changes in the expression and activity of drug metabolizing enzymes (DMEs) causing altered pharmacokinetic (PK) profiles of their substrate drugs (Sane & Sinz, 2017). If an alteration is clinically significant, individualized pharmacotherapy for the specific patient population is needed to ensure adequate treatment and avoid adverse drug reactions. Therefore, it is crucial to perform additional studies on DME expression and activity in different disease populations.

1.1. Phases of Metabolism

Hepatic metabolism is broadly classified into two phases which act to increase a chemical’s hydrophilicity facilitating its excretion (Cederbaum, 2015). Phase I involves oxidation, reduction, and hydrolysis reactions. Multiple enzyme families catalyze this phase. The most notable of which is the cytochrome P450 monooxygenation family (CYP). CYPs oxidize substrates by introducing one oxygen atom and utilizing nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor for the reaction. Alternatively, phase II is a conjugation phase where polar endogenous cofactors are conjugated with the substrate. An example of a phase II catalyzer is the uridine 5'-diphospho-glucuronosyltransferase family (UGT) that conjugate their substrates with glucuronic acid. Endogenous and exogenous chemicals do not necessarily undergo both metabolic phases to be cleared. Some would undergo phase I or phase II only. Others
would undergo both. Compounds hydrophilic enough to be excreted from the body unchanged do not undergo metabolism at all.

1.2. CYP2C Subfamily

CYP2C is a subfamily of cytochrome P450 enzymes that has four isoforms in humans: CYP2C8, CYP2C9, CYP2C18, and CYP2C19 (Goldstein, 2001). Members of this subfamily are involved in the metabolism of endogenous compounds such as arachidonic acid in addition to xenobiotics.

Arachidonic acid is an endogenous fatty acid that is found in cellular membranes. It is metabolized to active products via three enzymatic systems one of which is the CYP system. Studies by Rifkind, Lee, Chang, & Waxman (1995) have shown that both CYP2C8 and CYP2C9 play an important role in arachidonic acid metabolism through the CYP epoxygenase pathway. The resulting metabolites, called epoxyeicosatrienoic acids (EETs), are involved in numerous biological activities such as vascular smooth muscle homeostasis, endothelial calcium signaling, and regulation of cardiac muscles’ ion channels (Spector, Fang, Snyder, & Weintraub, 2004).

CYP2C8 is a CYP isoform that is involved in the hepatic clearance of nearly 5% of prescribed medications (Naraharisetti et al., 2010). The importance of this enzyme in drug development studies has not been recognized until the recent years (Backman, Filppula, Niemi, & Neuvonen, 2016). As a result, research on CYP2C8 phenotypes at Messenger Ribonucleic Acid (mRNA) level, protein expression, and enzyme activity, with respect to disease states is lacking. Since CYP2C8 is a major metabolic pathway for
several antidiabetic drugs, it is important to study its expression and activity in this population. For example, CYP2C8 is the primary metabolizing enzyme for the thiazolidinedione insulin sensitizers, rosiglitazone (Baldwin, Clarke, & Chenery, 1999) and pioglitazone (Jaakkola, Laitila, Neuvonen, & Backman, 2006), and the meglitinide insulin secretagogue, repaglinide (Bidstrup, Bjornsdottir, Sidelmann, Thomsen, & Hansen, 2003). In addition, CYP2C8 is involved in the metabolism of other antidiabetics as a minor pathway.

CYP2C9 is another enzyme that has an essential role in xenobiotic metabolism. It is the second most abundant CYP enzyme in the human liver, after CYP3A4, and is involved in phase I biotransformation of about 1/5 of all drugs. One of the widely prescribed CYP2C9 substrates is warfarin (Van Booven et al., 2010).

1.3. Effect of Diabetes Mellitus

According to the World Health Organization (WHO), the worldwide prevalence of diabetes has substantially increased to 8.5% of the population in 2014 (World Health Organization, 2017). A considerable number of patients with type 2 diabetes mellitus (T2DM) may have compromised hepatic function and other metabolic disorders. Although multiple research groups have studied the effects of T2DM on drug metabolism, the knowledge in this field is still limited to certain enzymes. For example, the in vivo activity of CYP2E1 is increased in obese T2DM patients using chlorzoxazone as a probe substrate (Lucas et al., 1998; Wang et al., 2003). CYP3A4 appears to be altered but there are conflicting results on the direction of its change (Dostalek, Court,
Yan, & Akhlaghi, 2011; Hu et al., 2014; Patoine et al., 2014). This conflict could be a result of species differences, variations in disease length, level of disease control and other factors.

To the best of our knowledge, there are no studies on the expression and activity of CYP2C8 and CYP2C9 in diabetic populations. However, there are studies showing altered pharmacokinetic profiles of clinically used drugs in diabetic states. Upon conducting a comprehensive review on PK in diabetes, thirty-five reports were found in the literature between January 1st, 2012 and September 4th, 2018 (Table 1). Reports prior to 2012 have been reviewed elsewhere (Dostalek, Akhlaghi, & Puzanovova, 2012). Several studies included drugs that are well known CYP2C8 or CYP2C9 substrates. For example, the non-steroidal anti-inflammatory drug (NSAID) diclofenac had altered PK parameters in diabetic animals as compared to non-diabetic controls (Ahmad, Iqbal, & Murtaza, 2012; Y. Li, Wei, Zhang, Wang, & Wu, 2012). An animal study published in 2016 by Zhou and colleagues, comparing diabetic to non-diabetic rats, reported five different drugs including glibenclamide. Glibenclamide (metabolized by CYP2C9 and CYP3A4) had alterations in all PK parameters measured: The area under the concentration-time curve until the last quantifiable value (AUC), clearance (CL), volume of distribution (Vd), and elimination half-life ($t_{1/2}$). Glibenclamide has also been reported to have different PK in diabetic rats by Y. Li, Wei, Zhang, Wang, and Wu (2012). The study included two routes of administration (oral and intravenous) and the PK differed under diabetic conditions for both routes. It is important to note however that not all substrates of CYP2C8 and 2C9 showed altered PK parameters in diabetics compared to non-diabetic groups. For
instance, the PK of rosiglitazone (Zhou et al., 2016) and losartan (Li et al., 2017) did not substantially differ between the groups. Involvement of alternative metabolic pathways and changes in absorption and/or distribution could be contributing to these mixed results.
Table 1. Influence of Diabetes Mellitus on Pharmacokinetics (Studies reported between 1/1/2012 – 9/4/2018)

| Drug            | Species | Major DMEs                                                                 | PK parameters | Non-diabetic (Mean ± SD) | Diabetic (Mean ± SD) | p-value       | Reference        |
|-----------------|---------|----------------------------------------------------------------------------|---------------|--------------------------|----------------------|--------------|-----------------|
| Acetaminophen   | Rabbit  | UGTs and SULTs                                                             |               | 0.55 ± 0.10               | 0.43 ± 0.15           | 0.07          | Bienert et al. 2012 |
|                 |         | ke (1/h)                                                                   |               | 1.31 ± 0.24               | 1.76 ± 0.49           | 0.03*         |                 |
|                 |         | t ½ (h)                                                                    |               | 3.52 ± 0.54               | 4.99 ± 0.89           | < 0.0008*     |                 |
|                 |         | CL (L/h)                                                                   |               | 1.70 ± 0.49               | 3.83 ± 0.87           | < 0.0001*     |                 |
|                 |         | Vd (L/kg)                                                                  |               | 40.35 ± 7.18              | 23.11 ± 3.98          | < 0.001*      |                 |
|                 |         | AUC (mg x h/L)                                                             |               | 67.04 ± 9.11              | 50.96 ± 6.32          | < 0.0008*     |                 |
|                 |         | Cmax (mg/L)                                                                |               | 0.083 ± 0.00              | 0.083 ± 0.00          | < 0.0001*     |                 |
|                 |         | Tmax (h)                                                                   |               | 0.89 ± 0.13               | 0.95 ± 0.28           | 0.65          |                 |
|                 |         | MRT (h)                                                                    |               |                         |                      |              |                 |
| Caffeine        | Mouse   | Cyp1a2 (CYP1A2 in humans)                                                  |               | 2.0 ± 1.1                 | 4.9 ± 0.9            | S            | Li et al. 2017   |
|                 |         | Cmax (μg/mL)                                                               |               | 491.1 ± 91.3              | 1418.0 ± 341.8        | S            |                 |
|                 |         | AUC (min*μg/mL)                                                           |               | 158 ± 71                  | 342 ± 236            | NS           |                 |
| Canagliflozin   | Rat     | Oxidation and glucuronidation (humans: UGT1A9 and UGT2B4)                   |               | 5.4 ± 0.6                 | 8.6 ± 1.6            | < 0.05*       | Zhou et al. 2016 |
|                 |         | AUC (μM*h)                                                                 |               | 5.8 ± 0.7                 | 9.7 ± 1.8            | < 0.05*       |                 |
|                 |         | AUCinf (μM*h)                                                              |               | 6.5 ± 0.8                 | 4.0 ± 0.8            | < 0.01*       |                 |
|                 |         | CL (mL/min per kg)                                                         |               | 3.4 ± 0.3                 | 2.4 ± 0.3            | < 0.01*       |                 |
|                 |         | Vdss (L/kg)                                                                |               | 6.2 ± 0.6                 | 7.6 ± 0.5            | < 0.01*       |                 |
|                 |         | t ½ (h)                                                                    |               |                         |                      |              |                 |
|                 |         | Activation: CYPs 3A4, 3A5, 2C19, 2C9, 2B6, 1A2                             |               |                         |                      |              |                 |
|                 |         | Clearance: Hydrolysis                                                      |               |                         |                      |              |                 |
| Clopidogrel     | Human   |                                                                           |               | 1.82 ± 1.86               | 2.34 ± 2.29          | NS           | Karaźniewicz-Lada et al. 2014 |
|                 |         | Cmax (ng/mL)                                                               |               | 1.39 ± 1.26               | 1.40 ± 0.79          | NS           |                 |
|                 |         | Tmax (h)                                                                   |               | 2.05 ± 1.54               | 1.33 ± 0.81          | NS           |                 |
|                 |         | AUC (ng x h/mL)                                                            |               | 4.95 ± 3.70               | 5.01 ± 4.11          | NS           |                 |
|                 |         | AUCinf (ng x h/mL)                                                         |               | 6.33 ± 4.32               | 6.07 ± 4.12          | NS           |                 |
|                          | Human |   |   |   |   |   |
|--------------------------|-------|---|---|---|---|---|
| **Clopidogrel**           |       |   |   |   |   |   |
| **Activation:**           | CYPs 3A4, 3A5, 2C19, 2C9, 2B6, 1A2 |   |   |   |   |   |
| **Clearance:**            | Hydrolysis and glucuronidation |   |   |   |   |   |
| **Plasma active metabolite level (ng/mL) after 0.5 hour of the loading dose** |   |   |   |   |   |   |
| **Plasma active metabolite level (ng/mL) after 3 hours of the loading dose** |   |   |   |   |   |   |
|                           |   |   |   |   |   |   |

| **Dexamethasone acetate (topical)** | Rat | CYP3A | AUC (ng/m) | Cmax (ng/mL) | Tmax (h) | (Mean ± SD) 299.90 ± 93.73 | 61.76 ± 16.13 | 11.5 ± 0 | (Mean ± SD) 319.88 ± 129.01 | 62.09 ± 10.51 | 11.5 ± 0 | 0.34 | Niijima et al. 2018 |

| **Dexamethasone sodium phosphate (topical)** | Rat | CYP3A | AUC (ng/m) | Cmax (ng/mL) | Tmax (h) | (Mean ± SD) 164080 ± 68990 | 29330 ± 6410 | 11.5 ± 0 | (Mean ± SD) 921880 ± 267750 | 131330 ± 41430 | 11.5 ± 0 | < 0.01* | Li et al. 2014 |

| **Dextromethorphan** | Mouse | Cyp2d22 (CYP2D6 in humans) | Cmax (μg/mL) | AUC (min*μg/mL) | t ½ (min) | (Mean ± SEM) 0.08 ± 0.03 | 19.1 ± 7.8 | 123 ± 30 | (Mean ± SEM) 0.17 ± 0.10 | 37.0 ± 23.3 | 120 ± 35 | NS | NS | NS | NS | Li et al. 2017 |

| **Diclofenac** | Rabbit | UGT2B7, CYP2C9, CYP3A4, CYP2C8 | Diclofenac sodium AUCinf (μg.h/mL) | Tmax (h) | C max (μg/ml) | (Mean ± SEM) 37.4 ± 0.21 | 1.67 ± 1.50 | (Mean ± SEM) 49.95 ± 0.22 | 2.15 ± 1.17 | < 0.05* | NS | Ahmad et al. 2012 |
|                      | Diclofenac potassium | Diclofenac Rat CYP2C9 ortholog | Docetaxel Rat CYP3A (humans: CYP3A4) |
|----------------------|----------------------|--------------------------|-------------------------------|
| **AUCinf (μg.h/mL)** | 80.73 ± 0.16, 1.71 ± 1.97 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **Tmax (h)**         | 26.83 ± 0.31, 0.86 ± 2.49 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **C max (μg/ml)**    | 1.2 ± 2.07, 0.83 ± 2.49 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **Ka (1/h)**         | 0.39 ± 3.11, 0.39 ± 3.11 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **MAT (1/h)**        | 1.86 ± 1.74, 1.77 ± 1.09 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **t ½α (h)**         | 12.84 ± 0.41, 0.43 ± 1.96 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **MRT (h)**          | 2.68 ± 1.45, 0.68 ± 1.8 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **Vd (L/Kg)**        | 2.18 ± 1.27, 2.91 ± 1.15 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **VSS (L/Kg)**       | 4.71 ± 0.63, 2.16 ± 0.995 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **Ke (1/h)**         | 0.68 ± 1.8, 0.29 ± 2.95 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **t ½ (h)**          | 0.63 ± 3.69, 0.63 ± 3.69 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **CL (ml/h/Kg)**     | 0.39 ± 3.11, 0.39 ± 3.11 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **CL (ml/h/Kg)**     | 1.86 ± 1.74, 1.77 ± 1.09 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |
| **(Mean ± SD)**      | 12.84 ± 0.41, 0.43 ± 1.96 | 170.08 ± 24.73, 11.29 ± 1.08 | 225 ± 44                      |

**Note:** NS indicates not significant, < 0.05* indicates significant at p < 0.05.
| Drug     | Species | Enzymes Involved | AUC (ng * h/mL) | CL/F (mL/min) | Cmax (ng/mL) | V/F (L) | CLR (mL/min) | Tmax (h) | t ½ (h) |
|----------|---------|-----------------|----------------|---------------|--------------|---------|-------------|---------|--------|
| Ertugliflozin | Human | UGT1A9 and UGT2B7 | Geometric mean (%CV) | 1236 (27) | 202 (27) | 219 (26) | 305 (39) | 1.68 (33) | 1.00 (1.00-2.00) | 17.7 ± 3.5 |
| Ethambutol | Human | Mainly excreted unchanged in urine and feces | Plasma concentration after 14 days (μg/mL) | 2.81 ± 0.30 | 3.6 ± 0.3 | 3.70 ± 0.64 | 4.3 ± 0.7 |

Sahasrabudhe et al. 2017

Babalik et al. 2013
| Drug                | Species | CYP Orthologs | Parameter                  | Value (Mean ± SD) | p Value   | Reference          |
|---------------------|---------|----------------|----------------------------|-------------------|-----------|--------------------|
| Glibenclamide       | Rat     | CYP2C9 and CYP3A4 orthologs | AUC (μM*h) | 5.1 ± 1.5 | < 0.01* | Zhou et al. 2016  |
|                     |         |                | AUCinf (μM*h)  | 10 ± 1.5  | 0.01*     |                    |
|                     |         |                | CL (ml/min per kg) | 5.3 ± 1.6 | 0.01*     |                    |
|                     |         |                | Vdss (L/kg)    | 6.8 ± 1.6 | 0.01*     |                    |
|                     |         |                | t ½ (h)        | 2.4 ± 0.2 | 0.01*     |                    |
|                     |         |                |                | 4.8 ± 0.8 | 0.01*     |                    |
| Glibenclamide       | Rat     | CYP2C9 and CYP3A4 orthologs | (Oral) T_max (min) | 84.78 ± 15.96 | < 0.01*  | Li et al. 2012    |
|                     |         |                | C_max (μg/mL)  | 0.26 ± 0.03 | 0.05*     |                    |
|                     |         |                | CL (L/min/kg)  | 0.09 ± 0.01 | 0.05*     |                    |
|                     |         |                | AUC (mg*min/L) | 57.75 ± 18.93 | < 0.01*  |                    |
|                     |         |                | (IV) t ½ (min) | 225.47 ± 25.34 | < 0.05*  |                    |
|                     |         |                | CL (x 10^3, L/min/kg) | 7.61 ± 1.53 | < 0.05*  |                    |
|                     |         |                | AUC (mg*min/L) | 509.52 ± 56.14 | < 0.05*  |                    |
| Glibenclamide       | Rat     | CYP2C9 and CYP3A4 orthologs | C_max (μg/mL) | 29.4 ± 0.7 | NA       | Samala et al. 2016|
|                     |         |                | T_max (h)      | 4          | NA       |                    |
|                     |         |                | AUC (μg/mL h)  | 109.3 ± 3.3 | NA       |                    |
|                     |         |                | AUCinf (μg/mL h)| 118.2 ± 3.5 | NA       |                    |
|                     |         |                | t ½ (h)        | 1.67 ± 0.1 | NA       |                    |
|                     |         |                | MRT (h)        | 4.11 ± 0.1 | NA       |                    |
|                     |         |                | CL (ml/min)    | 82.1 ± 1.4 | NA       |                    |
|                     |         |                | Vd (ml)        | 233.5 ± 7.5 | NA       |                    |
| Glimepiride         | Rat     | CYP2C9 ortholog (Humans: CYP2C9) | C_max (μg/mL) | 18.7 ± 0.8 | NA       | Veeresham et al. 2012|
|                     |         |                | T_max (h)      | 4          | NA       |                    |
|                     |         |                | AUC (μg/mL h)  | 161.7 ± 4.4 | NA       |                    |
|                     |         |                | AUCinf (μg/mL h)| 170.5 ± 6.7 | NA       |                    |
|                     |         |                | t ½ (h)        | 5.6 ± 1.0  | NA       |                    |
|                     |         |                | MRT (h)        | 10.7 ± 0.9 | NA       |                    |
|                |          |                          | CL (mL/min) | Vd (mL) | Mean (CV%) | Mean (CV%) | Mean (CV%) | Mean (CV%) | NS | S   | S   | NS | NS | NS | NA | Chadha et al. 2015 |
|----------------|----------|--------------------------|-------------|---------|------------|------------|------------|------------|----|-----|-----|----|----|----|----|-------------------------------|
| IgG            | Rat      | Metabolism by phagocytic cells or by their target antigen-containing cells | Vc (mL/kg) | 325.1 ± 12.5 | 53.2 (8.28) | 46.2 (10.3) | 0.0982 (11.8) | NA | NS  | S   | S   | NS | NS | NA |
|                |          |                          | Vp (mL/kg) | 56.3 ± 5.6 | 1.1 (7.6) | 0.185 (4.25) | 0.924 (6.78) | 0.76 | S   | S   | NS | NS | NS | NA |
|                |          |                          | CL (mL/d/kg) | 306.2 ± 12.3 | 51.5 ± 7.6 | 0.0982 (11.8) | 0.76 | NS  | S   | S   | NS | NS | NS |
|                |          |                          | Ka (1/d) | NA | NA | NA | NA | NA | NS | S   | S   | NS | NS | NS | NA |
|                |          |                          | F         | NA | NA | NA | NA | NA | NS | S   | S   | NS | NS | NS | NA |
|                |          |                          | t ½ (d) | NA | NA | NA | NA | NA | NS | S   | S   | NS | NS | NS | NA |
| Isoniazid      | Human    | Acetylation and hydrolysis | Plasma concentration after 14 days (μg/mL) | 5.83 (6.38) | 0.924 (6.78) | 0.808 (5.95) | 17.6 | S   | S   | NS | NS | NS | NA | Babalik et al. 2013 |
|                |          |                          | Plasma concentration after 30 days (μg/mL) | 0.0982 (11.8) | 0.924 (6.78) | 0.808 (5.95) | 17.6 | S   | S   | NS | NS | NS | NA |
| Isoniazid      | Human    | Acetylation and hydrolysis | TB alone (Median) | 3 | 11.05 | 2.6 | 10.39 | 1 | 0.6
|                |          |                          | TB + DM (Median) | 8.6 | 62.45 | 4.4 | 54.26 | 0.3 | 0.2
| Itopride       | Rat      | FMO                      | Cmax (μg/mL) | 2.72 ± 0.03 | 43.2 ± 0.07 | 3.92 ± 0.07 | 2 ± 0 | NS | NS | NS | Vunnam et al. 2015 |
|                |                          |                          | AUC (μg*h/mL) | AUCinf (μg*h/mL) | t ½ (h) | CL/F (mL/h/kg) | V/F (mL/kg) | 21.9 ± 0.118 | 27.49 ± 0.808 | 12.03 ± 1.11 | 26.71 ± 0.18 | 497.65 ± 3.09 | 42.49 ± 11.1 | NS | NS | NS | NS | NS |
|----------------|--------------------------|--------------------------|---------------|------------------|----------|----------------|-------------|---------------|---------------|---------------|---------------|----------------|---------------|----|----|----|----|----|
| Ketoconazole   | Human                    | CYP3A4                   |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |
|                |                          |                          |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |
| Lapatinib      | Rat                      | Primarily CYP3A4 in      |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |
|                |                          | humans (in addition to   |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |
|                |                          | 3A5, 2C19 and 2C8        |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |
| Losartan       | Mouse                    | Cyp2c29 (CYP2C9 in      |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |
|                |                          | humans)                  |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |
| Metformin      | Rat                      | Mainly excreted          |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |
|                |                          | unchanged in urine       |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |

|                |                          |                          |               |                  |          |                |             |               |               |               |               |                |               | NS | NS | NS | NS | NS |

Akhlaghi et al. 2012
Karbownik et al. 2018
Li et al. 2017
Zhou et al. 2016
| Metoprolol | Human CYP2D6 (preferred metabolism of R isomer) | Cmax (ng/mL) | Tmax (h) | AUCinf (ng/ml h) | MRT (h) | t ½ (h) | ke (1/h) | V/F (L/kg) | CL/F (L/h*kg) | Cmax (ng/mL) | Tmax (h) | Antunes et al. 2014 |
|------------|---------------------------------|-------------|--------|-----------------|--------|---------|---------|----------|-------------|-------------|--------|------------------|
| R (+) isomer |                                 | 22.89 (20.56, 64.26) | 1.50 (1.16, 2.15) | 62.65 (58.39, 225.03) | 6.71 (5.65, 10.14) | 7.74 (6.38, 11.24) | 0.09 (0.06, 0.13) | 35.38 (23.81, 87.46) | 5.29 (3.19, 7.48) | 41.42 (30.16, 67.51) | 1.50 (1.19, 2.15) | < 0.05* |
| S (-) isomer |                                 | 18.98 (12.53, 42.14) | 2.50 (1.55, 3.94) | 84.63 (41.48, 196.92) | 6.54 (4.78, 8.00) | 3.57 (2.60, 7.38) | 0.19 (0.12, 0.26) | 25.60 (15.95, 66.19) | 4.85 (1.97, 12.62) | 22.90 (12.97, 49.54) | 2.75 (1.94, 4.35) | < 0.05* |

*NS indicates not significant.
| Mexiletine | Rat | CYP2D6 and CYP1A2 in humans | Estimate (90% credible interval) | Estimate (90% credible interval) | Pardo et al. 2014 |
|-----------|-----|-----------------------------|-------------------------------|-------------------------------|------------------|
|           |     | (-)(R) Mexiletine AUCinf (ng.h/mL) | 154.2 (100.4–270.3) | 84.8 (43.6–167.0) | NA |
|           |     | CL/F (L/h*kg) | 32.4 (17.5–48.5) | 58.6 (17.4–80.1) | NA |
|           |     | Vd/F (L/kg) | 146.0 (95.3–244.3) | 600.4 (378.4–1383.0) | NA |
|           |     | (+)-(S) Mexiletine AUCinf (ng.h/mL) | 485.4 (302.9–856.0) | 265.8 (213.9–381.1) | NA |
|               |                | CL/F (L/h*kg) | Vd/F (L/kg) |            |            | NA | NA |
|---------------|----------------|--------------|------------|------------|------------|----|----|
| **Midazolam** | **Mouse**      | Cyp3a11      | (Mean ± SEM) | (Mean ± SEM) | NS         | NS | NS |
|               | (CYP3A4 in    |              | 0.30 ± 0.15 | 0.26 ± 0.10 | Li et al.  |    |    |
|               | humans)       |              | 36.7 ± 11.8 | 47.9 ± 18.5 | 2017       |    |    |
|               |                |              | 88 ± 38     | 140 ± 53    |            |    |    |
| **Nifedipine**| **Human**     | CYP3A4       | Median      | Median      | Filgueira  |    |    |
|               | (also by      | (25th–75th  | (25th–75th  | et al.     |            |    |    |
|               | CYP1A2 and    | percentiles) | percentiles | 2017       |            |    |    |
|               | CYP2A6)       |              |            |            |            |    |    |
|               |                | C max (ng/ml)| 26.41      | 23.52      |            | 0.23|    |
|               |                |              | (23.98–29.88)| (21.21–27.87)|            |    |    |
|               |                | Tmax (h)     | 1.79       | 1.48       |            | 0.46|    |
|               |                |              | (1.24–1.96) | (1.03–1.73) |            |    |    |
|               |                | AUC (ng.h/mL)| 235.99     | 202.23     |            | 0.38|    |
|               |                |              | (203.72–261.97)| (185.54–235.52) |            |    |    |
|               |                | Ke (1/h)     | 0.16       | 0.14       |            | 0.72|    |
|               |                |              | (0.15–0.18) | (0.13–0.25) |            |    |    |
|               |                | t ½ (h)      | 4.34       | 5.00       |            | 0.28|    |
|               |                |              | (3.87–4.64) | (4.45–5.84) |            |    |    |
|               |                | Vd/F (L)     | 560.96     | 609.40     |            | 0.87|    |
|               |                |              | (506.85–720.31)| (357.28–742.05) |            |    |    |
|               |                | CL/F (L/h)   | 84.77      | 98.94      |            | 0.38|    |
| Compound          | Species   | CYP Enzymes                          | Pharmacokinetic Parameters | Ref.            |
|-------------------|-----------|-------------------------------------|----------------------------|----------------|
| Omeprazole        | Mouse     | Cyp2c29 (CYP2C19 in humans)         | Cmax (μg/mL) (Mean ± SEM)   | Li et al. 2017 |
|                   |           |                                     | AUC (min*μg/mL) 0.6 ± 0.7 |                |
|                   |           |                                     | t ½ (min) 36.2 ± 31.7     |                |
|                   |           |                                     |                            |                |
|                   |           |                                     | AUC (min*μg/mL) 314.5 ± 195.4 |                |
|                   |           |                                     | t ½ (min) 56 ± 13         |                |
| Paclitaxel        | Rat       | CYP3A in rats (CYP3A4 and CYP2C8 in | AUCinf (μg.min/mL) 475 ± 25 | Lee et al. 2012 |
|                   |           | humans)                             | t ½ (min) 115 ± 10       |                |
|                   |           |                                     |                            |                |
|                   |           |                                     | 10 ± 2                    |                |
|                   |           |                                     |                            |                |
| Pantoprazole      | Human     | CYP2C19, 3A4, SULT                   | Plasma level (μg/mL) 0.34 ± 0.03 | Sapmaz et al. 2015 |
| Pioglitazone      | Rat       | CYP2C8, CYP2C9 and CYP3A4 orthologs  | Cmax (μg/mL) 5.55 ± 0.47  | Singh et al. 2013 |
|                   |           |                                     | Tmax (h) 4.00 ± 0.00      |                |
|                   |           |                                     | AUC (μg h/mL) 42.42 ± 4.13 |                |
|                   |           |                                     | t ½ (h) 3.62 ± 0.22      |                |
|                   |           |                                     | ke (1/h) 0.192 ± 0.01    |                |
|                   |           |                                     | MRT (h) 5.58 ± 0.14      |                |
|                   |           |                                     |                            |                |
|                   |           |                                     | AUC (μg.h/mL) 5.91 ± 0.52 |                |
|                   |           |                                     | t ½ (h) 4.00 ± 0.00      |                |
|                   |           |                                     |                            |                |
|                   |           |                                     | 51.19 ± 13.5             |                |
|                   |           |                                     |                            |                |
|                   |           |                                     | 3.86 ± 0.09              |                |
|                   |           |                                     |                            |                |
|                   |           |                                     | 0.180 ± 0.004            |                |
|                   |           |                                     |                            |                |
|                   |           |                                     | 5.84 ± 0.29              |                |
|                   |           |                                     |                            |                |
| Drug               | Species | Activation: CYPs | Plasma active metabolite level (ng/mL) after 0.5 hour of the loading dose | Plasma active metabolite level (ng/mL) after 3 hours of the loading dose | Reference |
|--------------------|---------|------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|------------|
| Prasugrel          | Human   | CYPs 3A4, 2B6, 2C19, 2C9 | ---                                                                      | ---                                                                      | Niijima et al. 2018 |
|                    |         | Clearance: Hydrolysis and glucuronide conjugation | ---                                                                      | ---                                                                      |            |
| Prednisone (free fraction) | Human   | CYP3A4 | median [25th quartile, 75th quartile] | median [25th quartile, 75th quartile] | Ionita et al. 2014 |
|                    |         |       | Tmax (h) | 2.04 [1.30, 2.20] | 3.00 [2.05, 4.08] | 0.02* |
|                    |         |       | Cmax/D (μg/L/mg) | 0.738 [0.621, 0.877] | 0.757 [0.655, 0.874] | 0.82 |
|                    |         |       | AUC/D (μg*h/L/mg) | 5.33 [4.53, 6.27] | 6.31 [5.64, 7.06] | 0.08 |
|                    |         |       | MTT (h) | 5.97 [5.49, 6.49] | 6.73 [6.22, 7.29] | 0.04* |
|                    |         |       | t ½ (h) | 3.29 [2.86, 3.77] | 3.49 [3.14, 3.88] | 0.48 |
|                    |         |       | CL/F (L/h*kg) | 2.15 | 1.78 | 0.20 |
| Drug                  | Species | Main Metabolism | Tmax (h) | Cmax/D (μg/L/mg) | AUC/D (μg*h/L/mg) | MTT (h) | t ½ (h) | V/F (L/kg) | Reference         |
|-----------------------|---------|-----------------|----------|------------------|-------------------|---------|---------|------------|------------------|
| Prednisolone (free fraction) | Human   | CYP3A4          | 1.01     | 3.90             | 17.7              | 4.47    | 2.83    | [1.80, 2.57] | Ionita et al. 2014 |
|                       |         |                 | 0.558, 1.65 | 3.25, 4.68       | 15.2, 20.4        | 4.09, 4.89 | 2.63, 3.04 | 10.2        |                  |
|                       |         |                 | 1.65     | 4.68             | 20.4              | 4.89    | 3.04    | [8.66, 12.0] |                  |
|                       |         |                 | Geometric mean [95% CI] | Geometric mean [95% CI] | Geometric mean [95% CI] | Geometric mean [95% CI] | Geometric mean [95% CI] | Geometric mean [95% CI] |                  |
|                       |         |                 | Median   | Median            | Median            | Median  | Median  | Median     |                  |
|                       |         |                 | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] |                  |
|                       |         |                 | 1.80     | 4.11             | 21.7              | 5.16    | 3.12    | 8.97       |                  |
|                       |         |                 | 1.04, 2.44 | 3.46, 4.90       | 19.5, 24.1        | 4.72, 5.65 | 2.90, 3.36 | [7.91, 10.2] |                  |
|                       |         |                 | 2.44     | 4.90             | 24.1              | 5.65    | 3.36    | [15.2, 20.4] |                  |
|                       |         |                 | Geometric mean [95% CI] | Geometric mean [95% CI] | Geometric mean [95% CI] | Geometric mean [95% CI] | Geometric mean [95% CI] | Geometric mean [95% CI] |                  |
|                       |         |                 | Median   | Median            | Median            | Median  | Median  | Median     |                  |
|                       |         |                 | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] | [25th quartile, 75th quartile] |                  |
|                       |         |                 | 0.01*    | 0.66             | 0.02*             | 0.02*   | 0.05*   | 0.05*      |                  |
| Pyrazinamide          | Human   | Mainly excreted unchanged in urine Some hepatic metabolism |         |                  |                  |         |         |           | Babalik et al. 2013 |
|                       |         |                 | Plasma concentration after 14 days (μg/mL) | (Mean ± SEM) | (Mean ± SEM) | (Mean ± SEM) |                  | NS |
|                       |         |                 | 23.4 ± 2.0 | 25.9 ± 1.4       |                  |         |         |           |                  |
| Drug                | Species | Metabolism | Plasma concentration after 30 days (μg/mL) | 27.9 ± 1.6 | 23.4 ± 1.9 | NS       | Kapur et al. 2013 |
|---------------------|---------|------------|------------------------------------------|------------|------------|----------|------------------|
| Remogliflozin etabonate | Human   | Possibly CYP and UGT | Dose: 500 mg | Geometric mean (CV%) | Geometric mean (CV%) | NA       | NA              |
|                     |         |            | AUCinf (ng·h/mL) | 36.8 (67) | 91.9 (46) | NA       | NA              |
|                     |         |            | C max (ng/ml) | 41.6 (81) | 83.9 (89) | NA       | NA              |
|                     |         |            | t ½ (h) | 0.263 (27) | 0.82 (69) | NA       | NA              |
|                     |         |            | Median (range) | 1.25 (0.33 – 2.50) | 0.75 (0.33 – 2.50) | NA       | NA              |
| Repaglinide         | Rat     | CYP3A4 and 2C8 in humans | Cmax (μg/mL) | (Mean ± SD) | (Mean ± SD) | NA       | Penta et al. 2017 |
|                     |         |            | T max (h) | 3.78 ± 0.53 | 7.4 ± 0.66 | NA       | NA              |
|                     |         |            | AUC (μg · h/mL) | 1 ± 0 | 1.16 ± 0.41 | NA       | NA              |
|                     |         |            | AUCinf (μg · h/mL) | 23.06 ± 3.18 | 41.39 ± 6.36 | NA       | NA              |
|                     |         |            | t ½ (h) | 23.18 ± 3.14 | 42.39 ± 6.54 | NA       | NA              |
|                     |         |            | MRT (h) | 3.05 ± 0.50 | 3.91 ± 1.69 | NA       | NA              |
|                     |         |            | CL (mL/h/kg) | 5.77 ± 0.40 | 6.21 ± 1.83 | NA       | NA              |
|                     |         |            | Vd (mL/kg) | 9.13 ± 1.73 | 4.58 ± 1.73 | NA       | NA              |
|                     |         |            | 39.62 ± 6.31 | 22.998 ± 2.37 | 4.58 ± 1.73 | NA       | NA              |
| Rifampin            | Human   | Deacetylation | Plasma concentration after 14 days (μg/mL) | (Mean ± SEM) | (Mean ± SEM) | < 0.05* | Babalik et al. 2013 |
|                     |         |            | Plasma concentration after 30 days (μg/mL) | 5.1 ± 0.5 | 2.9 ± 0.2 | < 0.05* | Babalik et al. 2013 |
|                     |         |            | 5.4 ± 0.5 | 3.2 ± 0.5 | < 0.05* | Babalik et al. 2013 |
| Drug          | Species | Metabolism | PK Parameters | TB patients | TB + T2DM patients | Medellin-Garibay et al. 2015 |
|---------------|---------|------------|---------------|-------------|--------------------|-----------------------------|
| Rifampin      | Human   | Deacetylation | Non-compartmental PK | | | |
| | | | Cmax (mg/L) | 11.41 ± 3.8 | 12.10 ± 5.1 | NS |
| | | | Tmax (h) | 2.32 ± 1.4 | 2.98 ± 1.9 | NS |
| | | | AUC (mg · h/L) | 82.60 ± 35.5 | 97.52 ± 36.7 | NS |
| | | | AUCinf (mg · h/L) | 87.07 ± 39.9 | 107.73 ± 56.3 | NS |
| | | | MRT (h) | 7.67 ± 2.7 | 9.07 ± 5.0 | NS |
| | | | One-compartment open model | | | |
| | | | Ka (1/h) | 1.79 (0.8–2.8) | 1.80 (0.4–3.4) | NS |
| | | | t ½α (h) | 0.39 (0.2–0.9) | 0.39 (0.2–1.8) | NS |
| | | | Vd (L/kg) | 0.84 ± 0.31 | 0.63 ± 0.21 | NS |
| | | | ke (1/h) | 0.21 ± 0.1 | 0.19 ± 0.08 | NS |
| | | | t ½ (h) | 4.31 ± 1.7 | 3.97 ± 1.5 | NS |
| | | | CL (L/h) | 8.62 ± 3.9 | 6.04 ± 1.8 | < 0.05* |
| | | | | | | |
| Rosiglitazone | Rat | CYP2C22 (ortholog of human CYP2C8) | AUC (μM*h) | (Mean ± SD) 40 ± 12 | (Mean ± SD) 32 ± 7 | NS |
| | | | AUCinf (μM*h) | 40 ± 12 | 32 ± 7 | NS |
| | | | CL (mL/min per kg) | 1.2 ± 0.3 | 1.5 ± 0.3 | NS |
| | | | Vdss (L/kg) | 0.3 ± 0.0 | 0.2 ± 0.0 | NS |
| | | | t ½ (h) | 2.9 ± 0.2 | 2.7 ± 0.1 | NS |
| Salicylic acid | Rat | Mainly excreted unchanged in urine | CL/F (mL/h*kg) | Mean (CV%) 68.0 (6.57) | Mean (CV%) 94.6 (4.10) | NA |
| Sunitinib     | Rabbit | CYP3A4 | AUC (ng x h/mL) | (Mean ± SD) 2303.6 ± 1069.1 | (Mean ± SD) 3785.8 ± 1282.5 | NA |
| | | | AUCinf (ng x h/mL) | 2425.0 ± 1077.5 | 4699.4 ± 1338.3 | < 0.01* |

* NS indicates non-significant differences.
| Tacrolimus | Human | CYP3A4 |
|-----------|-------|--------|
| t ½ (h) | 23.2 ± 7.6 | 31.6 ± 19.1 |
| CL (L/h) | 12.1 ± 5.4 | 5.7 ± 1.6 |
| Vd (L) | 418.2 ± 223.4 | 242.3 ± 120.0 |
| Cmax (ng/mL) | 92.1 ± 22.1 | 149.2 ± 33.7 |
| Tmax (h) | 7.2 ± 0.8 | 8.8 ± 2.1 |
| MRT (h) | 23.3 ± 2.8 | 25.3 ± 5.8 |
| Tacrolimus | Human | CYP3A4 |
| Tmax (h) | median (interquartile range) |
| Cmax (ng/mL per mg dose) | 1.5 (1.4–2.0) | 3.0 (2.0–4.0) |
| AUC (ng*h/mL per mg dose) | 3.2 (2.3–5.2) | 5.8 (3.8–8.3) |
| CL (L/hour/kg) | 20.6 (12.9–41.9) | 37.7 (37.2–63.9) |
| CL/F (L/h) | 0.28 (0.13–0.58) | 0.13 (0.08–0.17) |

| Tedizolid | Human | Sulfate conjugation |
|-----------|-------|---------------------|
| Cmax (mg/L) | mean ± SD or median (range) |
| Tmax (h) | 2.7 ± 1.1 | 1.5 ± 0.5 |
| t ½ (h) | 2.5 (2.0–3.0) | 5.9 (1.2–8.0) |
| AUC (mg*h/L) | 8.9 ± 2.2 | 9.1 ± 3.6 |
| CL/F (L/h) | 28.7 ± 9.6 | 18.5 ± 9.7 |
| Vd/F (L) | 11.4 ± 3.3 | 15.0 ± 6.8 |
| Tedizolid | Human | Sulfate conjugation |
| Healthy volunteers | mean ± SD or median (range) |
| diabetic foot patients | mean ± SD or median (range) |

| Chitnis et al. 2013 | 0.012* |
|---------------------|--------|
| 0.044* |
| 0.037* |

| Stainton et al. 2018 | 0.005* |
|---------------------|--------|
| 0.003* |
| 0.932 |
| 0.004* |
| 0.481 |
| 0.143 |
| Tramadol (+) isomer | Human CYP3A4, 2B6, 2D6, then Sulfation or glucuronidation | Median (25th–75th percentile) | Median (25th–75th percentile) | De Moraes et al. 2014 |
|---------------------|------------------------------------------------------------|-------------------------------|-------------------------------|------------------------|
| AUCinf (ng*h/mL)    | 1311.8 (1042.2–2166.6)                                     | 977.5 (912.2–1432.3)          | NS                           |
| Cmax (ng/mL)        | 167.5 (137.5–253.1)                                        | 144.8 (139.2–149.0)           | NS                           |
| Tmax (h)            | 1.5 (1.3–2.0)                                               | 1.3 (1.2–1.8)                 | NS                           |
| CL/F (L/h)          | 38.3 (23.8–48.3)                                            | 51.15 (35.1–54.8)             | NS                           |
| t ½ (h)             | 7.6 (6.6–9.1)                                               | 7.5 (6.2–11.2)                | NS                           |
| Vd/F (L)            | 357.3 (286.7–509.1)                                         | 384.2 (382.3–400.4)           | NS                           |
| AUCinf (ng*h/mL)    | 1264.2 (851.5–1496.4)                                       | 1222.9 (870.8–2081.3)         | NS                           |
| Cmax (ng/mL)        | 159.5 (119.7–223.6)                                         | 128.7 (123.7–156.8)           | NS                           |
| Tmax (h)            | 1.5 (1.2–2.0)                                               | 1.3 (1.2–2.0)                 | NS                           |
| CL/F (L/h)          | 39.9                                                       | 40.9                          | NS                           |
| Troglitazone | Rat   | SULT (ortholog of human SULT1A1) | AUC (μM*h) | AUCinf (μM*h) | CL (mL/min per kg) | Vdss (L/kg) | t ½ (h) | AUC (μM*h) | AUCinf (μM*h) | CL (mL/min per kg) | Vdss (L/kg) | t ½ (h) | AUC (μM*h) | AUCinf (μM*h) | CL (mL/min per kg) | Vdss (L/kg) | t ½ (h) |
|-------------|-------|----------------------------------|-------------|---------------|-----------------|-------------|---------|-------------|---------------|-----------------|-------------|---------|-------------|---------------|-----------------|-------------|---------|
|             |       |                                  | (Mean ± SD) | (Mean ± SD)   |                 |             |         | (Mean ± SD) | (Mean ± SD)   |                 |             |         | (Mean ± SD) | (Mean ± SD)   |                 |             |         |
| Troglitazone | Rat   | SULT (ortholog of human SULT1A1) | AUC (μM*h)  | AUCinf (μM*h) | CL (mL/min per kg) | Vdss (L/kg) | t ½ (h) | AUC (μM*h)  | AUCinf (μM*h) | CL (mL/min per kg) | Vdss (L/kg) | t ½ (h) |
| (Mean ± SD) |       |                                  | 0.6 ± 0.1   | 0.6 ± 0.1     | 63 ± 10         | 1.6 ± 0.6   | 2.0 ± 1.2 | 0.6 ± 0.1   | 0.6 ± 0.1     | 63 ± 10         | 1.6 ± 0.6   | 2.0 ± 1.2 | 0.6 ± 0.1   | 0.6 ± 0.1     | 63 ± 10         | 1.6 ± 0.6   | 2.0 ± 1.2 |
1.4. Effect of Non-alcoholic Fatty Liver Disease

NAFLD is a health issue that has been on the rise globally. It is defined as an abnormal fat accumulation in the liver without significant alcohol consumption or other secondary causes. NAFLD is further sub-classified to non-alcoholic fatty liver (NAFL) where there is only simple steatosis and non-alcoholic steatohepatitis (NASH) where steatosis is accompanied by liver cell injury and inflammation and in some cases fibrosis (Chalasani et al., 2012). There are many inconsistent reports on NAFLD prevalence. This is mainly due to the different methods used for diagnosis. In a recent meta-analysis, the estimated global prevalence was approximately 25% when including patients diagnosed by imaging methods only (Younossi et al., 2016). The effect of NAFLD on DMEs has become a topic of interest. As in the case of T2DM, the effect seems to differ for each CYP450 enzyme. A clinical study in a pediatric population reported no change in CYP2C9 enzyme activity in the NASH group compared to the healthy group (H. Li et al., 2017). An in vitro study using human liver microsomes (HLM) from healthy and NAFLD adults showed a significant increase in CYP2C9 enzyme activity measured with two probe substrates, diclofenac and tolbutamide (Fisher et al., 2009). Concerning CYP2C8, the study by Fisher and his colleagues (2009) is the only study reporting this enzyme’s phenotypes in NAFLD. Their results showed no change in CYP2C8 enzyme activity and mRNA level with disease progression. However, there was a non-statistically significant decrease in protein level. We believe that these results are not conclusive. More research is warranted for CYP2C8 and 2C9 expression and activity in NAFLD with a larger sample size.
1.5. Warfarin as a Probe Substrate

Warfarin is an anticoagulant that exerts its pharmacological action by interfering with the function of vitamin K as an essential component of the clotting cascade. The pharmacokinetics of warfarin has been extensively studied. Following oral administration, it is easily absorbed through the gastrointestinal tract and then highly bound to plasma proteins once in the main bloodstream which limits its distribution. Hepatic metabolism is the main route of clearance with little to no role of kidneys in excreting the parent compound (Park, 1988). The approved dosage form is a mixture of S- and R- enantiomers. These enantiomers have shown different potency and pharmacokinetic profiles (Choonara, Haynes, Cholerton, Breckenridge, & Park, 1986). S-warfarin is more potent as measured by the level of increase in prothrombin time (Park, 1988). Regarding PK differences, S-warfarin is majorly metabolized by CYP2C9 to 7-hydroxy warfarin while R-warfarin goes through multiple pathways and CYP2C9 plays a minor role in its biotransformation. Findings from pharmacogenetic research suggest that CYP2C9 is the main CYP enzyme implicated in the clearance of warfarin and the inter-individual variability to this drug ("COUMADIN Prescribing information," 2011). The clinical relevance of S-warfarin coupled with its sensitivity to CYP2C9 alterations makes it a suitable probe substrate for studies on CYP2C9 activity.
Chapter 2

Methodology

2.1 Chemicals and Supplies

S-warfarin, S-7-hydroxywarfarin, and S-7-hydroxywarfarin-d5 were obtained from Toronto Research Chemicals (North York, Ontario, Canada). Individual Human liver tissue samples and Xtreme pool of 200 human liver microsomes were purchased from Sekisui XenoTech (Kansas City, KS, USA). Tetrasodium salt of reduced nicotinamide adenine dinucleotide phosphate (NADPH) was purchased from EMD Millipore (Burlington, MA, USA). LC/MS grade acetonitrile and methanol were obtained from ThermoFisher Scientific (Waltham, MA, USA). All other solvents were of analytical grade.

2.2 Liver Tissue Grading and Processing

Individual human liver tissue samples were commercially obtained from Sekisui XenoTech. Demographics and diabetic status of the liver donors were provided by the supplying company. However, their identities were not known. Therefore, the research is exempt from review by The University of Rhode Island institutional review board (IRB) under exempt category # 4. Grading of liver tissues for NAFLD presence and severity was done by a histopathologist collaborating with our lab (Dr. Suzanne Delamonte, MD). Liver tissues were then categorized as: normal, NAFL, or NASH as described in detail by Jamwal et al. (2018).
Human liver microsomes were prepared in our lab by homogenization of the liver tissue samples using automated Omni Bead Ruptor 24 homogenizer (Omni International, Kennesaw, GA, USA). Homogenates were then differentially centrifuged using Eppendorf’s 5810R Centrifuge (Eppendorf, Hamburg, Germany) then Beckman Coulter’s ultracentrifuge (Beckman Coulter, Brea, CA) to obtain microsome pellets that were resuspended in glycerol buffer and stored in -80°C for later use (Jamwal et al., 2017).

To account for the effects of enzyme inducers and inhibitors potentially taken by liver donors prior to death, our lab recently completed a project to detect several commonly used drugs which possess CYP450 induction or inhibition properties in the liver bank (Barlock & Jamwal, 2018. Manuscript in preparation). Three CYP2C8 inducers, two CYP2C9 inducers, and eleven CYP2C9 inhibitors were detected.

Table 2 shows the donors’ demographics and the most frequently detected CYP2C8/2C9 inducers and inhibitors in the liver bank (n=106). CYP2C8’s and CYP2C9’s mRNA and protein levels were measured for all 106 livers in our lab using validated procedures (Jamwal et al., 2017). Table 3 shows the donor’s demographics and the most frequently detected CYP2C9 inducers and inhibitors in a subset of the liver bank that was included in measuring CYP2C9 activity (n=76). Limited sample quantities prevented CYP2C9 activity measurement of the whole bank.
Table 2. Donors’ demographics and detected CYP2C8/2C9 inducers and inhibitors in all livers (n=106)

| Age (mean ± SD) | Non-diabetic/no NAFLD (n=21) | Diabetic only (n=21) | NAFLD only (n=32) | Diabetic + NAFLD (n=32) |
|----------------|-----------------------------|---------------------|------------------|------------------------|
| (minimum, maximum) | 49.43 ± 16.14 | 48.62 ± 13.63 | 52.31 ± 10.87 | 53.28 ± 9.45 |
| Gender (%) | Females (42.9) | Females (33.3) | Females (50.0) | Females (56.3) |
| | Males (57.1) | Males (66.7) | Males (50.0) | Males (43.8) |
| Ethnicity (%) | Caucasians (81.0) | Caucasians (76.2) | Caucasians (90.6) | Caucasians (90.6) |
| | African Americans (19.0) | African Americans (19.0) | African Americans (3.1) | African Americans (3.1) |
| | Hispanics (0.0) | Hispanics (4.8) | Hispanics (6.3) | Hispanics (6.3) |
| BMI (%) | <30 (66.7) | <30 (52.4) | <30 (50.0) | <30 (34.4) |
| | ≥30 (33.3) | ≥30 (47.6) | ≥30 (50.0) | ≥30 (65.6) |
| CYP2C8 Polymorphism (%) | *1/*1 (100.0) | *1/*1 (81.0) | *1/*1 (71.9) | *1/*1 (81.3) |
| | *1/*3 (0.0) | *1/*3 (19.0) | *1/*3 (28.1) | *1/*3 (15.6) |
| | *3/*3 (0.0) | *3/*3 (0.0) | *3/*3 (0.0) | *3/*3 (3.1) |
| CYP2C9 Polymorphism (%) | *1/*1 (100.0) | *1/*1 (81.0) | *1/*1 (68.8) | *1/*1 (81.3) |
| | *1/*2 (0.0) | *1/*2 (19.0) | *1/*2 (31.3) | *1/*2 (15.6) |
| | *2/*2 (0.0) | *2/*2 (0.0) | *2/*2 (0.0) | *2/*2 (3.1) |
| Dexamethasone (CYP2C8 inducer) (%) | Present (19.0) | Present (19.0) | Present (25.0) | Present (19.4) |
| | Absent (81.0) | Absent (81.0) | Absent (75.0) | Absent (80.6) |
| Phenytoin (CYP2C8/2C9 inducer) (%) | Present (38.1) | Present (23.8) | Present (31.3) | Present (32.3) |
|-----------------------------------|----------------|----------------|----------------|----------------|
|                                   | Absent (61.9)  | Absent (76.2)  | Absent (68.8)  | Absent (67.7)  |
| Tetrahydrocannabinol (CYP2C9 inhibitor) (%) | Present (57.1) | Present (57.1) | Present (75.0) | Present (80.6) |
|                                   | Absent (42.9)  | Absent (42.9)  | Absent (25.0)  | Absent (19.4)  |
### Table 3. Donor’s demographics and detected CYP2C9 inducers/inhibitors in livers included in CYP2C9 activity measurements (n=76)

|                          | Non-diabetic/no NAFLD (n=16) | Diabetic only (n=16) | NAFLD only (n=25) | Diabetic + NAFLD (n=19) |
|--------------------------|------------------------------|----------------------|--------------------|------------------------|
| **Age** (mean ± SD)      | 49.13 ± 16.42                | 45.44 ± 12.88        | 52.68 ± 11.8       | 52.47 ± 8.87           |
| (minimum, maximum)       | (21,73)                      | (21,70)              | (33,76)            | (38,74)                |
| **Gender (%)**           | Females (43.8)               | Females (31.3)       | Females (48.0)     | Females (68.4)         |
|                          | Males (56.3)                 | Males (68.8)         | Males (52.0)       | Males (31.6)           |
| **Ethnicity (%)**        | Caucasians (75.0)            | Caucasians (75.0)    | Caucasians (88.0)  | Caucasians (94.7)      |
|                          | African Americans (25.0)     | African Americans (18.8) | African Americans (4.0) | African Americans (5.3) |
|                          | Hispanics (0.0)              | Hispanics (6.3)      | Hispanics (8.0)    | Hispanics (0.0)        |
| **BMI (%)**              | <30 (68.8)                   | <30 (50.0)           | <30 (48.0)         | <30 (31.6)             |
|                          | ≥30 (31.3)                   | ≥30 (50.0)           | ≥30 (52.0)         | ≥30 (68.4)             |
| **CYP2C9 Polymorphism (%)** | *1/*1 (100.0)               | *1/*1 (81.3)         | *1/*1 (76.0)       | *1/*1 (73.7)           |
|                          | *1/*2 (0.0)                  | *1/*2 (18.8)         | *1/*2 (24.0)       | *1/*2 (21.1)           |
|                          | *2/*2 (0.0)                  | *2/*2 (0.0)          | *2/*2 (0.0)        | *2/*2 (5.3)            |
| **Phenytoin (CYP2C9 inducer) (%)** | Present (50.0)               | Present (31.3)       | Present (32.0)     | Present (26.3)         |
|                          | Absent (50.0)                | Absent (68.8)        | Absent (68.0)      | Absent (73.7)          |
| **Tetrahydrocannabinol (CYP2C9 inhibitor) (%)** | Present (56.3)               | Present (56.3)       | Present (68.0)     | Present (84.2)         |
|                          | Absent (43.8)                | Absent (43.8)        | Absent (32.0)      | Absent (15.8)          |
2.3 Preliminary Experiments for CYP2C9 Activity Measurement

Detection system linearity was assessed by injecting a wide concentration range of S-warfarin (0.5 – 64 uM) and S-7OH-warfarin (0.25 – 64 uM) pure standards and plotting them against their peak areas as measured by LC-MS/MS.

Sekisui XenoTech Xtreme pool of 200 human liver microsomes was used to determine the optimal incubation settings prior to measurements in donor-specific liver microsomes.

Time and protein linearity experiments were performed to determine incubation times and microsomal protein concentrations where product formation is within the linear range.

In time linearity experiment, incubations were carried out in 100 mM Phosphate buffer containing 3 mM MgCl2 and 1 mM EDTA (pH 7.4). The incubation mixture consisted of 0.2 mg/mL HLM, 3.85 uM S-warfarin, and 1.3 mM NADPH. A water bath set at 37 °C was used to simulate body temperature. Aliquots were withdrawn from the incubation plate at 0, 20, 40, 60, 80, 100, 120, and 140 minutes and added to a quenching plate containing ice cold acetonitrile and internal standard (IS) (2 uM S-7-hydroxywarfarin-d5) to stop the reaction. Afterwards, the samples were centrifuged at 3200 g for 10 minutes and the resulting supernatants were injected into LC-MS/MS for metabolite quantification. Quantity of the metabolite S-7-hydroxywarfarin formed was plotted against incubation time to determine the linear range.
In protein linearity experiment, the same incubation mixture and settings were implemented except for HLM concentration where a range of (0.025 – 1 mg/mL) was used. The reaction was stopped after 50 minutes as this time point was found to be within the linear range in the previous experiment. Samples were then centrifuged, and the metabolite quantified by injecting the supernatants in LC-MS/MS.

After determining the optimal incubation times and HLM concentrations, an experiment to generate Michaelis-Menten plot was performed to find the Km and Vmax values of our system and ensure that the substrate concentration we use for the main experiments is below Km to prevent system saturation. A range of S-warfarin concentrations (0.5 – 64 uM) was incubated with 0.4 mg/mL HLM for 45 and 60 minutes (HLM concentration and incubation times were determined suitable by protein and time linearity experiments). The reaction was carried out in 100 mM Phosphate buffer as described earlier.

2.4 Measurement of S-Warfarin Depletion and S-7-Hydroxywarfarin Formation

After finalizing the protocol with the optimal experimental settings, the main experiments were commenced using HLM samples from the individual donors. Each HLM sample (n=95) was incubated in a separate well in the 96-well plate. The incubation mixture consisted of 0.4 mg/mL HLM, 8 uM S-warfarin, 100 mM Phosphate buffer, and 1.3 mM NADPH (total volume=180 uL). The mixture was preincubated in a water bath set at 37 °C for 5 minutes prior to adding NADPH. Following preincubation, the incubation was started by adding NADPH and immediately transferring a 20 uL aliquot
to a quenching plate containing 80 uL quenching solution (2 uM S-7-hydroxywarfarin-d5 as internal standard in ice cold acetonitrile) to measure the substrate at time zero. Four more 20 uL aliquots were taken at 12.5, 25, 37.5, and 50 minutes and added to the quenching plate. The quenching plate was then centrifuged, and the resulting supernatants were injected into LC-MS/MS.

Two calibration curves were created using known concentrations of S-warfarin (curve 1) and S-7OH-warfarin (curve 2) to interpolate concentrations of unknowns using linear regression. The remaining concentration of S-warfarin at different time points was used to measure its depletion and calculate the intrinsic clearance. The final aliquot at 50 minutes was used to measure S-7OH-warfarin formation to determine CYP2C9 activity.

2.5 Quantification of S-Warfarin and S-7-Hydroxywarfarin

The LC-MS/MS instrument consisted of ACQUITY UPLC System equipped with a Vanguard pre-column, an ACQUITY UPLC BEH C18 column, and an autosampler. Attached to the UPLC system is an API 3200™ Triple Quad mass spectrometer with an electrospray ionization probe set at positive ion mode.

Chromatographic separation using a gradient elution mode was performed. Target column temperature was 50 °C. The mobile phase constituted of 10 mM ammonium acetate with 5% acetonitrile at pH 4.85 (A) and 100% acetonitrile (B). The flow rate was set at 0.25 mL/min and the gradient of A and B solvents was started as
follows: A:B 95:5 (v/v) until 1 minute; A:B 75:25 (v/v) until 2.5 minutes; A:B 30:70 (v/v) until 3 minutes; A:B 10:90 (v/v) until 4 minutes; A:B 95:5 (v/v) until 5 minutes.

2.6 Intrinsic Clearance Calculation

As indicated earlier, S-warfarin’s depletion over incubation time was used to calculate its intrinsic clearance in HLM samples. This method, known as in vitro t ½ approach, was performed as described by Obach et al. (1997). Briefly, resulting peak heights of the remaining substrate and the internal standard were recorded for each sample to calculate substrate peak height/IS peak height ratios. After that, the ratios were transformed to percentages using the ratio at time zero as %100 and then transformed again to the logarithmic form. The resulting values were plotted against their respective incubation times and slopes were calculated by doing linear regression analysis. Finally, the following formulas were utilized to calculate the intrinsic clearance (adapted from Obach, 1998):

\[
\text{slope} = -k
\]

\[
t_{\frac{1}{2}} = -\frac{0.693}{k}
\]

\[
\text{CL}_{\text{int}} = \frac{0.693 \times \text{incubation volume (mL)} \times 45 \text{ mg microsomes} \times 20 \text{ g liver in vitro } t_{\frac{1}{2}} \times \text{mg microsomes} \times \text{liver weight (g)} \times \text{body weight (kg)}}{\text{45 mg microsomes x 20 g liver}}
\]
2.7 Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics version 24.0 for Windows (Released 2016. Armonk, NY: IBM Corp.). Normality was assessed using Shapiro-Wilk’s test. Depending on normality results, one-way ANOVA or Kruskal-Wallis H test was chosen for testing the differences between more than two groups. The level of significance was set to be < 0.05. Calculation of Km and Vmax values and generation of graphs was done utilizing GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com).
Chapter 3

Results

3.1 Preliminary Experiments

LC-MS/MS system linearity was observed for injected concentrations versus responses up until the highest concentration used for both S-warfarin and S-7OH-warfarin (figures 1A and 1B respectively).

![Figure 1](image)

**Figure 1.** LC-MS/MS system linearity for injected analyte concentration versus detected response. A. S-warfarin B. S-7OH-warfarin

S-7OH-warfarin formation was within the linear range for incubation times between 20 and 60 minutes (figure 2A) and HLM concentrations between 0.1 mg/mL and 1 mg/mL (figure 2B).
Figure 2. Range of linearity of S-7OH-warfarin formation with respect to A. incubation time B. microsomal concentration

Two Michaelis-Menten plots were generated (figure 4). Vmax was 6.188 picomole/min/mg HLM and 11.12 picomole/min/mg HLM after 45 and 60 minutes of incubation respectively. Km was approximately 13.12 uM.

Figure 3. Michaelis-Menten Plots at 45 and 60 minutes incubation times
3.2 Effects of Diabetes and NAFLD on S-warfarin Intrinsic Clearance

Intrinsic clearance of S-warfarin per liver sample are shown in table 4. The
distribution of CLint values did not differ significantly when compared between groups
of different diabetic and NAFLD status (Table 5).

3.3 Effects of Diabetes and NAFLD on CYP2C8 and 2C9 Expression and Activity

CYP2C9 activity did not seem to be significantly affected by either diabetes nor
NAFLD status (Table 6). CYP2C8 mRNA and protein expression in addition to CYP2C9
mRNA expression showed similar results of non-significant effect (Tables 7 and 8).
Interestingly, however, CYP2C9 protein expression was significantly different between
the groups (Figure 4 and Table 8).

Figure 4. Boxplots representing the distribution of CYP2C9 protein levels across NAFLD
subgroups within the diabetic group, SD = Significant difference
Table 4. Intrinsic clearance (mL/min/kg) values for individual liver samples

| Liver ID | CLint  | Liver ID | CLint  | Liver ID | CLint  | Liver ID | CLint  | Liver ID | CLint  |
|----------|--------|----------|--------|----------|--------|----------|--------|----------|--------|
| 412      | 0.0000718 | 490      | 0.0000550 | 540      | 0.0000145 | 743      | 0.0000118 | 815      | 0.0000219 |
| 415      | 0.0000595 | 493      | 0.0000804 | 542      | 0.0000056 | 749      | 0.0000419 | 816      | 0.0000145 |
| 425      | 0.0000280 | 495      | 0.000147  | 543      | 0.0000215 | 750      | 0.0000079 | 818      | 0.0000148 |
| 447      | 0.0000009 | 498      | 0.000229  | 545      | 0.000350  | 752      | 0.000031  | 821      | 0.0001027 |
| 448      | 0.0000532 | 502      | 0.000012  | 546      | 0.000015  | 762      | 0.0000202 | 847      | 0.0000004 |
| 450      | 0.0000580 | 508      | 0.000223  | 548      | 0.000011  | 768      | 0.000361  | 850      | 0.000035  |
| 461      | 0.0000727 | 510      | 0.000094  | 715      | 0.000451  | 772      | 0.000098  | 879      | 0.000255  |
| 465      | 0.0000984 | 527      | 0.00027   | 717      | 0.000206  | 791      | 0.000842  | 892      | 0.0000192 |
| 466      | 0.000343  | 531      | 0.000094  | 723      | 0.000315  | 799      | 0.000758  | 944      | 0.0000527 |
| 467      | 0.0000065 | 533      | 0.000131  | 740      | 0.000825  | 802      | 0.000537  | 981      | 0.000014  |
| 473      | 0.000027  | 536      | 0.000081  | 741      | 0.001050  | 803      | 0.000656  | 991      | 0.000014  |
Table 5. Effect of diabetes and NAFLD on S-warfarin’s intrinsic clearance

|                      | Non-diabetic/no NAFLD (n=12) | Diabetic only (n=9) | NAFLD only (n=20) | Diabetic + NAFLD (n=13) |
|----------------------|-------------------------------|---------------------|-------------------|-------------------------|
| CL\text{int} (mL/min/kg) | 4.3 ± 2.68                    | 3.5 ± 3.04          | 2.93 ± 2.54       | 2.61 ± 3.93             |
| Mean ± SD\text{p}    |                               |                     |                   |                         |
| p-value              |                               |                     | 0.099             |                         |

p-values reported from data analysis using Kruskal-Wallis Test  * all mean and SD values are multiplied by $10^5$ for simplification (for example: 4.3 is actually 0.000043)
Table 6. Effect of diabetes and NAFLD on CYP2C9 activity

| CYP2C9 activity (pmol/min/mg HLM) | Non-diabetic/no NAFLD (n=16) | Diabetic only (n=16) | NAFLD only (n=25) | Diabetic + NAFLD (n=19) |
|----------------------------------|-----------------------------|----------------------|-------------------|------------------------|
| Mean ± SD                        | 3.3 ± 2.66                  | 3.54 ± 3.16          | 3.37 ± 3.43       | 2.14 ± 2.65            |
| p-value                          |                             |                      | 0.664             |                        |

p-values reported from data analysis using Kruskal-Wallis Test
**Table 7.** Effect of diabetes and NAFLD on CYP2C8 and CYP2C9 mRNA expression

|                      | Non-diabetic/no NAFLD (n=21) | Diabetic only (n=21) | NAFLD only (n=32) | Diabetic + NAFLD (n=32) |
|----------------------|------------------------------|----------------------|-------------------|------------------------|
| **CYP2C8 mRNA**      |                              |                      |                   |                        |
| Mean ± SD            | 3.18 ± 5.19                  | 2.87 ± 3.32          | 2.69 ± 3.82       | 1.82 ± 2.25            |
| p-value              |                              |                      | 0.541             |                        |
| **CYP2C9 mRNA**      |                              |                      |                   |                        |
| Mean ± SD            | 5.91 ± 11.53                 | 3.59 ± 5.22          | 2.78 ± 4.03       | 2.02 ± 2.28            |
| p-value              |                              |                      | 0.354             |                        |

p-values reported from data analysis using Kruskal-Wallis Test
Table 8. Effect of diabetes and NAFLD on CYP2C8 and CYP2C9 protein expression

|                  | Non-diabetic/no NAFLD (n=20) | Diabetic only (n=21) | NAFLD only (n=32) | Diabetic + NAFLD (n=30) |
|------------------|------------------------------|----------------------|-------------------|------------------------|
| **CYP2C8**       |                              |                      |                   |                        |
| Protein (pmol/mg HLM) Mean ± SD | 47.66 ± 55.08 | 40.23 ± 32.65 | 29.08 ± 28.1 | 27.02 ± 21.56 |
| p-value          |                              |                      |                   |                        |
|                  |                              |                      |                   |                        |
| **CYP2C9**       |                              |                      |                   |                        |
| Protein (pmol/mg HLM) Mean ± SD | 57.77 ± 30.5 | 70.28 ± 49.26 | 43.75 ± 17.28 | 42.51 ± 19.12 |
| p-value          |                              |                      |                   |                        |

p-values reported from data analysis using Kruskal-Wallis Test, * significant result
Pairwise comparisons using the Dunn-Bonferroni approach was performed as post hoc analysis to determine which groups showed the significant difference found in CYP2C9 protein expression (Table 9). Both the Diabetic only/ NAFLD only and Diabetic only/ Diabetic + NAFLD pairwise comparisons were significant. Other comparisons were not significant.

**Table 9. Pairwise comparisons of CYP2C9 protein levels distribution between disease groups**

| Pair                             | p-value |
|---------------------------------|---------|
| Diabetic + NAFLD/ NAFLD only    | 0.864   |
| Diabetic + NAFLD/ Normal        | 0.100   |
| Diabetic + NAFLD/ Diabetic only | 0.019*  |
| NAFLD only/ Normal              | 0.130   |
| NAFLD only/ Diabetic only       | 0.026*  |
| Normal/ Diabetic only           | 0.534   |

* significant result

To determine the magnitude of CYP2C9 protein level variability that is accounted by demographical data, multiple linear regression analysis was done. Age, gender, ethnicity, obesity, CYP2C9 polymorphism, diabetes/NAFLD status in addition to presence of phenytoin (CYP2C9 inducer) were all included as predictors in building the following regression model:

\[
\text{CYP2C9 protein level (pmol/mg HLM)} = 59.436 - 0.077 \text{ (age)} + 17.385 \text{ (gender)} - 5.903 \text{ (ethnicity)} + 6.14 \text{ (BMI)} - 4.869 \text{ (polymorphism)} - 7.058 \text{ (diabetes/NAFLD status)} - 6.872 \text{ (phenytoin)}
\]

The regression model was significant (p-value: 0.015) which indicates that at least one of the predictors had a regression coefficient not equal to zero. When
analyzing each predictor, gender and diabetic/NAFLD status were the only significant predictors (p-values: 0.007 and 0.018 respectively). A newer model was created incorporating only these predictors:

\[
\text{CYP2C9 protein level (pmol/mg HLM) = 5.923 + 15.141 (gender) – 6.674 (diabetes/NAFLD status)}
\]

The adjusted R-square value is 0.111. In other words, 11.1% of the variability in CYP2C9 protein expression can be explained by gender, diabetes, and NAFLD effects.

Multiple linear regression analysis was also performed to determine if any of the predictors mentioned above contribute to the variability in CYP2C8 mRNA, CYP2C8 protein, and CYP2C9 mRNA expression. Presence of phenytoin was the only significant predictor of CYP2C8 mRNA level (p-value = 0.001). Age and diabetic/NAFLD status were predictors of CYP2C8 expression (p-values: 0.035 and 0.046 respectively). As for CYP2C9 mRNA expression, presence of phenytoin and diabetic/NAFLD status were significant predictors (p-values: 0.01 and 0.026 respectively).

Although tetrahydrocannabinol (CYP2C9 inhibitor) was present in most of the livers. There was no notable influence of its presence on CYP2C9 activity and S-warfarin intrinsic clearance measured in HLM. This is not surprising when considering the process involved in hepatic microsomal preparation which is expected to remove much of the compounds present in the liver.
Chapter 4

Discussion and Conclusions

Our findings have shown that CYP2C8’s mRNA and protein expression were not altered under the influence of two disease states: diabetes mellitus and NAFLD. Similarly, CYP2C9’s mRNA expression, activity levels, and S-warfarin’s intrinsic clearance showed no change. However, CYP2C9 protein levels significantly decreased in the NAFLD group and the combined diabetic and NAFLD group as compared to the diabetic only group. Multiple linear regression analysis showed that both diseases in addition to gender can explain about 11% of CYP2C9 protein level variability.

Several mechanisms have been proposed for the effect of diseases on hepatic drug metabolizing enzymes expression. Both diabetes mellitus (Sada et al., 2016; Norouzirad, Gonzalez-Muniesa, & Ghasemi, 2017) and NAFLD (Suzuki, Shinjo, Arai, Kanai, & Goda, 2014) are associated with a state of hypoxia. As reported by Simms & D’Amico (1996), there is a notable increased expression of cytokine receptors on cell surfaces in low oxygen states facilitating the intracellular effects of cytokines. Cytokines of interest to drug metabolism include Interleukin-1β and Interferon-γ which activate multiple intracellular signaling pathways that can eventually phosphorylate amino acid residues of some CYPs altering their activities (Fradette & Du Souich, 2004). Furthermore, these cytokines can activate intracellular cascades that lead to transcriptional modifications of CYP genes in the nucleus causing changes in protein expression. Increased activity of ubiquitin proteasome system in hypoxia has been
suggested as a post-transcriptional down-regulator of some CYPs (du Souich & Fradette, 2011). Apart from hypoxia, other conditions such as inflammation also play a role in CYPs alterations. Interleukin-6, which is a cytokine released in inflammation, was found to decrease mRNA levels of the nuclear receptors Constitutive Androstane Receptor (CAR) and Pregnane X Receptor (PXR). Both of which are crucial for induction of CYP2 family genes (Pascussi et al., 2000).

There are some limitations to this study. The limited samples’ quantities prevented intrinsic clearance measurement using the metabolite formation approach which is a better-defined method than the in vitro half-life approach (Jones & Houston, 2004). Additionally, the lack of information on how long the enzyme inducers were taken may cause inaccuracies. This is due to the possibility that some liver donors took an inducer for a period long enough to exert its effect on enzyme levels while others were exposed to an inducer for a short period before death. Furthermore, the low representation of different ethnicities and people with polymorphic forms of CYP2C8 and CYP2C9 hinders the generalization of our findings. Finally, the nature of in vitro studies does not allow for direct clinical predictions as multiple factors in vivo can play a role in drug’s clearance such as liver blood flow and plasma protein binding.

In conclusion, this study provides some insight into CYP2C8 and CYP2C9 expression and function in diabetic and/or NAFLD populations. Future studies in vivo are needed to determine the clinical significance of these findings.
Bibliography

Ahmad, M., Iqbal, M., & Murtaza, G. (2012). Comparison of bioavailability and pharmacokinetics of diclofenac sodium and diclofenac potassium in normal and alloxan-diabetic rabbits. *Pakistan Journal of Pharmaceutical Sciences, 25*(2), 301-306.

Akhlaghi, F., Dostalek, M., Falck, P., Mendonza, A. E., Amundsen, R., Gohh, R. Y., & Åsberg, A. (2012). The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus. *Therapeutic Drug Monitoring, 34*(1), 38-45.

Antunes Nde, J., Cavalli, R. C., Marques, M. P., Moises, E. C., & Lanchote, V. L. (2015). Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients. *British Journal of Clinical Pharmacology, 79*(4), 605-616.

Atif M., A. M., uz-zaman QM., Asif M., Syed Sulaiman SA., Shafie AA., I Masood, Minhas U. and Us-saqib N. (2011). Glipizide Pharmacokinetics in Healthy and Diabetic Volunteers. *Tropical Journal of Pharmaceutical Research, 10*(2), 147-152.

Babalik, A., Ulus, I. H., Bakirci, N., Kuyucu, T., Arpag, H., Dagyildizi, L., & Capaner, E. (2013). Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. *Antimicrobial Agents and Chemotherapy, 57*(11), 5740-5742.

Backman, J. T., Filppula, A. M., Niemi, M., & Neuvonen, P. J. (2016). Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. *Pharmacological Reviews, 68*(1), 168-241.
Baldwin, S. J., Clarke, S. E., & Chenery, R. J. (1999). Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. *British Journal of Clinical Pharmacology*, 48(3), 424-432.

Bidstrup, T. B., Bjornsdottir, I., Sidelmann, U. G., Thomsen, M. S., & Hansen, K. T. (2003). CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. *British Journal of Clinical Pharmacology*, 56(3), 305-314.

Bienert, A., Kaminska, A., Olszewski, J., Gracz, J., Grabowski, T., Wolc, A., & Grzeskowiak, E. (2012). Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan. *Pharmacological Reports*, 64(2), 421-427.

Brooks, H. B., Geeganage, S., Kahl, S. D., Montrose, C., Sittampalam, S., Smith, M. C., & Weidner, J. R. (2004). Basics of Enzymatic Assays for HTS. In G. S. Sittampalam, N. P. Coussens, K. Brimacombe, A. Grossman, M. Arkin, D. Auld, C. Austin, J. Baell, B. Bejcek, J. M. M. Caaveiro, T. D. Y. Chung, J. L. Dahlin, V. Devanaryan, T. L. Foley, M. Glicksman, M. D. Hall, J. V. Haas, J. Inglese, P. W. Iversen, S. D. Kahl, S. C. Kales, M. Lal-Nag, Z. Li, J. McGee, O. McManus, T. Riss, O. J. Trask, Jr., J. R. Weidner, M. J. Wildey, M. Xia, & X. Xu (Eds.), *Assay Guidance Manual*. Bethesda (MD).

Bystrom, J., Wray, J. A., Sugden, M. C., Holness, M. J., Swales, K. E., Warner, T. D., Edin, M. L., Zeldin, D. C., Gilroy, D. W., Bishop-Bailey, D. (2011). Endogenous epoxygenases are modulators of monocyte/macrophage activity. *PLoS One*, 6(10), e26591.
Cao, Y., DuBois, D. C., Almon, R. R., & Jusko, W. J. (2012). Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats. *Biopharmaceutics & Drug Disposition, 33*(6), 285-291.

Cederbaum, A. I. (2015). Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications. *Redox Biology, 4*, 60-73.

Chadha, G. S., & Morris, M. E. (2015). Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. *The American Association of Pharmaceutical Scientists Journal, 17*(4), 965-975.

Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., Sanyal, A. J. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology, 55*(6), 2005-2023.

Chitnis, S. D., Ogasawara, K., Schniedewind, B., Gohh, R. Y., Christians, U., & Akhlaghi, F. (2013). Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. *Xenobiotica, 43*(7), 641-649.

Choonara, I. A., Haynes, B. P., Cholerton, S., Breckenridge, A. M., & Park, B. K. (1986). Enantiomers of warfarin and vitamin K1 metabolism. *British Journal of Clinical Pharmacology, 22*(6), 729-732.
Cooper, D. Y., Schleyer, H., Levin, S. S., Eisenhardt, R. H., Novack, B. G., & Rosenthal, O. (1979). A reevaluation of the role of cytochrome P-450 as the terminal oxidase in hepatic microsomal mixed function oxidase catalyzed reactions. *Drug Metabolism Reviews*, 10(2), 153-185.

COUMADIN Prescribing information. (2011). Retrieved from [https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf). Accessed February 2018.

de Moraes, N. V., Lauretti, G. R., & Lanchote, V. L. (2014). Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers. *Journal of Pharmacy and Pharmacology*, 66(9), 1222-1230.

Dhade, S. R., Lokegaonkar, D. V., & Bhutkar, S. P. (2017). Effect of Gymnema Sylvestre on the pharmacokinetics of sitagliptin phosphate in type II diabetes mellitus. *International Journal of Pharmaceutical Sciences and Research*, 8(3), 1160-1167.

Dostalek, M., Akhlaghi, F., & Puzanovova, M. (2012). Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. *Clinical Pharmacokinetics*, 51(8), 481-499.

Dostalek, M., Court, M. H., Yan, B., & Akhlaghi, F. (2011). Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. *British Journal of Pharmacology*, 163(5), 937-947.
du Souich, P., & Fradette, C. (2011). The effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression. Expert Opinion on Drug Metabolism & Toxicology, 7(9), 1083-1100.

Filgueira, G. C. D. O., Filgueira, O. A. S., Carvalho, D. M., Marques, M. P., Moisés, E. C. D., Duarte, G., Lanchote, V. L., Cavalli, R. C. (2017). Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. British Journal of Clinical Pharmacology, 83(7), 1571-1579.

Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P., Ferguson, S. S., & Cherrington, N. J. (2009). Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metabolism and Disposition, 37(10), 2087-2094.

Flora, D. R., Rettie, A. E., Brundage, R. C., & Tracy, T. S. (2017). CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites. The Journal of Clinical Pharmacology, 57(3), 382-393.

Fradette, C., & Du Souich, P. (2004). Effect of hypoxia on cytochrome P450 activity and expression. Current Drug Metabolism, 5(3), 257-271.

Furge, L. L., & Guengerich, F. P. (2006). Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction. Biochemistry and Molecular Biology Education, 34(2), 66-74.
Goldstein, J. A. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. *British Journal of Clinical Pharmacology, 52*(4), 349-355.

Hodgson, E. (1979). Comparative aspects of the distribution of cytochrome P-450 dependent mono-oxygenase systems: an overview. *Drug Metabolism Reviews, 10*(1), 15-33.

Hu, N., Hu, M., Duan, R., Liu, C., Guo, H., Zhang, M., Yu, Y., Wang, X., Liu, L., Liu, X. (2014). Increased levels of fatty acids contributed to induction of hepatic CYP3A4 activity induced by diabetes - in vitro evidence from HepG2 cell and Fa2N-4 cell lines. *Journal Of Pharmacological Sciences, 124*(4), 433-444.

Ionita, I. A., Ogasawara, K., Gohh, R. Y., & Akhlaghi, F. (2014). Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus. *Therapeutic Drug Monitoring, 36*(4), 448-455.

Jaakkola, T., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2006). Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. *Basic & Clinical Pharmacology & Toxicology, 99*(1), 44-51.

Jamwal, R., Barlock, B. J., Adusumalli, S., Ogasawara, K., Simons, B. L., & Akhlaghi, F. (2017). Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS. *Journal of Proteome Research, 16*(11), 4134-4143.

Jamwal, R., de la Monte, S. M., Ogasawara, K., Adusumalli, S., Barlock, B. B., & Akhlaghi, F. (2018). Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased
CYP3A4 Protein Expression and Activity in Human Liver. *Molecular Pharmaceutics*, 15(7), 2621-2632.

Jones, H. M., & Houston, J. B. (2004). Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. *Drug Metabolism and Disposition*, 32(9), 973-982.

Ju, W., Peng, K., Yang, S., Sun, H., Sampson, M., & Wang, M. Z. (2014). A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasma. *Austin journal of analytical and pharmaceutical chemistry*, 1(2).

Kapur, A., O’Connor-Semmes, R., Hussey, E. K., Dobbins, R. L., Tao, W., Hompesch, M., Smith, G. A., Polli, J. W., James Jr, C. D., Mikoshiba, I., Nunez, D. J. (2013). First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. *BMC Pharmacology and Toxicology*, 14, 26.

Karaźniewicz-Łada, M., Danielak, D., Burchardt, P., & Główka, F. (2014). The influence of diabetic status on the pharmacokinetics of clopidogrel and its metabolites in patients suffered from cardiovascular diseases. *Journal of Medical Science*, 83(3), 7.

Karbownik, A., Szałek, E., Sobańska, K., Klupczynska, A., Plewa, S., Grabowski, T., Wolc, A., Moch, M., Kokot, Z. J., Grześkowiak, E. (2018). A pharmacokinetic study on lapatinib in type 2 diabetic rats. *Pharmacological Reports*, 70(2), 191-195.
Kohl, C., & Steinkellner, M. (2000). Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. *Drug Metabolism and Disposition, 28*(2), 161-168.

Kroetz, D. L., & Zeldin, D. C. (2002). Cytochrome P450 pathways of arachidonic acid metabolism. *Current Opinion In Lipidology, 13*(3), 273-283.

Laerd Statistics (2015). Kruskal-Wallis H test using SPSS Statistics. Statistical tutorials and software guides. Retrieved from [https://statistics.laerd.com/](https://statistics.laerd.com/). Accessed March 2018.

Laerd Statistics (2015). Mann-Whitney U test using SPSS Statistics. Statistical tutorials and software guides. Retrieved from [https://statistics.laerd.com/](https://statistics.laerd.com/). Accessed March 2018.

Laerd Statistics (2015). Statistical tutorials and software guides. Retrieved from [https://statistics.laerd.com/](https://statistics.laerd.com/). Accessed March 2018.

Lee, D. Y., Lee, M. G., Shin, H. S., & Lee, I. (2007). Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. *Journal of Pharmacy and Pharmaceutical Sciences, 10*(4), 420-433.

Lee, J. H., Lee, A., Oh, J. H., & Lee, Y. J. (2012). Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats. *Biopharmaceutics & Drug Disposition, 33*(8), 474-486.
Li, H., Canet, M. J., Clarke, J. D., Billheimer, D., Xanthakos, S. A., Lavine, J. E., Erickson, R. P., Cherrington, N. J. (2017). Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis. *Drug Metabolism and Disposition, 45*(12), 1317-1325.

Li, H., Clarke, J. D., Dzierlenga, A. L., Bear, J., Goedken, M. J., & Cherrington, N. J. (2017). In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. *Journal of Biochemical and Molecular Toxicology, 31*(2).

Li, S. S., Song, Z. H., Xiong, L. Q., Zhang, Q., Liu, Q., & Li, G. F. (2014). The percutaneous permeability and absorption of dexamethasone esters in diabetic rats: a preliminary study. *Drug Delivery, 21*(1), 17-25.

Li, Y., Wei, Y., Zhang, F., Wang, D., & Wu, X. (2012). Changes in the pharmacokinetics of glibenclamide in rats with streptozotocin-induced diabetes mellitus. *Acta Pharmaceutica Sinica B, 2*(2), 196-202.

Lucas, D., Farez, C., Bardou, L. G., Vaisse, J., Attali, J. R., & Valensi, P. (1998). Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. *Fundamental & Clinical Pharmacology, 12*(5), 553-558.

Medellin-Garibay, S. E., Cortez-Espinosa, N., Milan-Segovia, R. C., Magana-Aquino, M., Vargas-Morales, J. M., Gonzalez-Amaro, R., Portales-Perez, D. P., Romano-Moreno, S. (2015). Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters. *Antimicrobial Agents and Chemotherapy, 59*(12), 7707-7714.
Naraharisetti, S. B., Lin, Y. S., Rieder, M. J., Marcian, K. D., Psaty, B. M., Thummel, K. E., & Totah, R. A. (2010). Human liver expression of CYP2C8: gender, age, and genotype effects. *Drug Metabolism and Disposition, 38*(6), 889-893.

Nath, A., & Atkins, W. M. (2006). A theoretical validation of the substrate depletion approach to determining kinetic parameters. *Drug Metabolism and Disposition, 34*(9), 1433-1435.

Niijima, S., Ohmori, T., & Kario, K. (2018). Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel. *Thrombosis Journal, 16*, 5.

Norouzirad, R., Gonzalez-Muniesa, P., & Ghasemi, A. (2017). Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate. *Oxidative Medicine and Cellular Longevity, 2017*, 5350267.

Obach, R. S. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. *Drug Metabolism and Disposition, 25*(12), 1359-1369.

Obach, R. S. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. *Drug Metabolism and Disposition, 27*(11), 1350-1359.

Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., MacIntyre, F., Rance, D. J., Wastall, P. (1997). The prediction of human pharmacokinetic parameters from
preclinical and in vitro metabolism data. *Journal of Pharmacology and Experimental Therapeutics*, 283(1), 46-58.

Obach, R. S., & Reed-Hagen, A. E. (2002). Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. *Drug Metabolism and Disposition*, 30(7), 831-837.

Pardo Campos Godoy, A. L., Martinez, E. Z., Marques, M. P., de Carvalho Leone, A., Barbosa Coelho, E., & Lucia Lanchote, V. (2014). Influence of experimental diabetes and insulin treatment on the enantioselective pharmacokinetics of mexiletine and its metabolites. *Canadian Journal of Physiology and Pharmacology*, 92(3), 263-266.

Park, B. K. (1988). Warfarin: metabolism and mode of action. *Biochemical Pharmacology*, 37(1), 19-27.

Pascussi, J. M., Gerbal-Chaloin, S., Pichard-Garcia, L., Daujat, M., Fabre, J. M., Maurel, P., & Vilarem, M. J. (2000). Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. *Biochemical and Biophysical Research Communications*, 274(3), 707-713.

Patoine, D., Petit, M., Pilote, S., Picard, F., Drolet, B., & Simard, C. (2014). Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes. *Pharmacology Research & Perspectives*, 2(6), e00082.
Penta, J., Gorre, T., & Yellu, N. R. (2017). Pharmacokinetic and pharmacodynamic interaction study of curcumin with repaglinide in normal and diabetic rats. *Journal of Global Trends in Pharmaceutical Sciences, 8*(3), 4130-4137.

Requena-Mendez, A., Davies, G., Waterhouse, D., Ardrey, A., Jave, O., Lopez-Romero, S. L., Ward, S. A., Moore, D. A. (2014). Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. *Antimicrobial Agents and Chemotherapy, 58*(12), 7164-7170.

Rettie, A. E., Eddy, A. C., Heimark, L. D., Gibaldi, M., & Trager, W. F. (1989). Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. *Drug Metabolism and Disposition, 17*(3), 265-270.

Rifkind, A. B., Lee, C., Chang, T. K., & Waxman, D. J. (1995). Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. *Archives of Biochemistry and Biophysics, 320*(2), 380-389.

Ruikar, D. B., & Rajput, S. J. (2012). Optimization of the in vitro oxidative biotransformation of glimepiride as a model substrate for cytochrome p450 using factorial design. *DARU Journal of Pharmaceutical Sciences, 20*(1), 38.

Sada, K., Nishikawa, T., Kukidome, D., Yoshinaga, T., Kajihara, N., Sonoda, K., Senokuchi, T., Motoshima, H., Matsumura, T. Araki, E. (2016). Hyperglycemia Induces Cellular Hypoxia through Production of Mitochondrial ROS Followed by Suppression of Aquaporin-1. *PLoS One, 11*(7), e0158619.
Sahasrabudhe, V., Terra, S. G., Hickman, A., Saur, D., Shi, H., O'Gorman, M., Zhou, Z., Cutler, D. L. (2017). The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus. *The Journal of Clinical Pharmacology, 57*(11), 1432-1443.

Samala, S., & Veeresham, C. (2016). Pharmacokinetic and Pharmacodynamic Interaction of Boswellic Acids and Andrographolide with Glyburide in Diabetic Rats: Including Its PK/PD Modeling. *Phytotherapy Research, 30*(3), 496-502.

Sane, R., & Sinz, M. (2017). Chapter 1 - Introduction of Drug Metabolism and Overview of Disease Effect on Drug Metabolism A2 - Xie, Wen. *Drug Metabolism in Diseases* (pp. 1-19). Boston: Academic Press.

Sapmaz, F., Kalkan, I. H., Suslu, I., Demirci, H., Atasoy, P., & Guliter, S. (2015). Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus. *Journal of Digestive Diseases, 16*(9), 531-536.

Simms, H., & D'Amico, R. (1996). Regulation of polymorphonuclear leukocyte cytokine receptor expression: the role of altered oxygen tensions and matrix proteins. *The Journal of Immunology, 157*(8), 3605-3616.

Singh, J., & Patel, S. C. (2013). Pharmacokinetic changes of fluvoxamine and pioglitazone by drug drug interaction in healthy, diabetic and depressive rats. *International Journal of Pharmacy and Pharmaceutical Sciences, 5*(1), 352-355.
Spector, A. A., Fang, X., Snyder, G. D., & Weintraub, N. L. (2004). Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. *Progress in Lipid Research*, 43(1), 55-90.

Stanton, S. M., Monogue, M. L., Baummer-Carr, A., Shepard, A. K., Nugent, J. F., Kuti, J. L., & Nicolau, D. P. (2018). Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via In Vivo Microdialysis. *Antimicrobial Agents and Chemotherapy*, 62(1).

Suzuki, T., Shinjo, S., Arai, T., Kanai, M., & Goda, N. (2014). Hypoxia and fatty liver. *World Journal of Gastroenterology*, 20(41), 15087-15097.

Szalek, E., Karbownik, A., Sobanska, K., Grabowski, T., Polom, W., Lewandowska, M., Wolc, A., Matuszewski, M., Grzeskowiak, E. (2014). The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits. *Pharmacological Reports*, 66(5), 892-896.

Van Booven, D., Marsh, S., McLeod, H., Carrillo, M. W., Sangkuhl, K., Klein, T. E., & Altman, R. B. (2010). Cytochrome P450 2C9-CYP2C9. *Pharmacogenetics and Genomics*, 20(4), 277-281.

Veeresham, C., Sujatha, S., & Rani, T. S. (2012). Effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal and streptozotocin-induced diabetic rats. *Natural Product Communications*, 7(10), 1283-1286.

Vunnam, R. R., Sriharsha, S. N., & Rajesham, V. V. (2015). Pharmacokinetic drug interactions of Gliclazide and itopride in normal and diabetic rats. *International Journal of Pharmacy and Pharmaceutical Sciences*, 7(10), 307-311.
Wang, Z., Hall, S. D., Maya, J. F., Li, L., Asghar, A., & Gorski, J. C. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. *British Journal of Clinical Pharmacology, 55*(1), 77-85.

World Health Organization. (2017). Diabetes. Retrieved from [http://www.who.int/mediacentre/factsheets/fs312/en/](http://www.who.int/mediacentre/factsheets/fs312/en/). Accessed February 2018.

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology, 64*(1), 73-84.

Zhou, X., Rougee, L. R., Bedwell, D. W., Cramer, J. W., Mohutsky, M. A., Calvert, N. A., Moulton, R. D., Cassidy, K. C., Yumibe, N. P., Adams, L. A., Ruterbories, K. J. (2016). Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats. *Drug Metabolism and Disposition, 44*(8), 1184-1192.